Las acciones de Vanda Pharmaceuticals se disparan en un 25,46% impulsadas por los avances en el desarrollo de terapias psicodélicas y los progresos regulatorios.

Vanda Pharmaceuticals Inc. shares surged 25.46% in pre-market trading on January 2, 2026, driven by strategic advancements in its psychedelic therapy pipeline and regulatory progress. The rally reflects renewed investor confidence in the company’s ability to capitalize on high-potential therapeutic areas.

The jump follows a key partnership with a European biotech firm, granting Vanda exclusive rights to co-develop a novel psychedelic-assisted treatment for depression.

Positive Phase II trial results for its lead candidate VVX-001 in late 2025—showing a 60% reduction in depressive symptoms—further strengthened the stock’s momentum. The FDA’s Breakthrough Therapy Designation for VVX-001 in December 2025 also accelerated regulatory expectations, reducing approval timelines and operational risks.

Streamlined management reforms announced in late 2025 aligned the company with broader industry trends in psychedelic medicine. Investors are now focused on Q1 2026 earnings reports and updates on EU regulatory strategies as potential catalysts for sustained growth. The pre-market surge underscores market optimism about Vanda’s positioning in an evolving mental health innovation landscape.